201 related articles for article (PubMed ID: 24351059)
21. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
22. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
24. A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.
Byrne S; Mason D
N Z Med J; 2012 Feb; 125(1350):37-44. PubMed ID: 22382255
[TBL] [Abstract][Full Text] [Related]
25. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
26. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
Prosperini L; Mancinelli CR; De Giglio L; De Angelis F; Barletta V; Pozzilli C
Mult Scler; 2014 Apr; 20(5):566-76. PubMed ID: 23999607
[TBL] [Abstract][Full Text] [Related]
27. Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment.
Shirani A; Zhao Y; Petkau J; Gustafson P; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
Biomed Res Int; 2015; 2015():451912. PubMed ID: 25922836
[TBL] [Abstract][Full Text] [Related]
28. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
29. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
30. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
31. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[TBL] [Abstract][Full Text] [Related]
32. Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability.
Vermersch P; de Seze J; Stojkovic T; Hautecoeur P;
J Neurol; 2002 Feb; 249(2):184-7. PubMed ID: 11985384
[TBL] [Abstract][Full Text] [Related]
33. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
34. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
Fragomeni MO; Bichuetti DB; Oliveira EML
Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
36. Scoring treatment response in patients with relapsing multiple sclerosis.
Sormani MP; Rio J; Tintorè M; Signori A; Li D; Cornelisse P; Stubinski B; Stromillo Ml; Montalban X; De Stefano N
Mult Scler; 2013 Apr; 19(5):605-12. PubMed ID: 23012253
[TBL] [Abstract][Full Text] [Related]
37. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
[TBL] [Abstract][Full Text] [Related]
38. [Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients].
Patrucco L; Rojas JI; Cristiano E
Rev Neurol; 2010 May; 50(9):529-32. PubMed ID: 20443171
[TBL] [Abstract][Full Text] [Related]
39. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B
Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705
[TBL] [Abstract][Full Text] [Related]
40. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
